Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
DISHMAN PHARMA | SANOFI INDIA | DISHMAN PHARMA/ SANOFI INDIA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | 42.5 | 59.0% | View Chart |
P/BV | x | 3.3 | 8.7 | 38.7% | View Chart |
Dividend Yield | % | 0.7 | 1.0 | 66.0% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
SANOFI INDIA Dec-18 |
DISHMAN PHARMA/ SANOFI INDIA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 6,840 | 5.5% | |
Low | Rs | 129 | 4,630 | 2.8% | |
Sales per share (Unadj.) | Rs | 197.8 | 1,203.1 | 16.4% | |
Earnings per share (Unadj.) | Rs | 21.2 | 165.3 | 12.8% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 209.9 | 16.5% | |
Dividends per share (Unadj.) | Rs | 2.00 | 84.00 | 2.4% | |
Dividend yield (eoy) | % | 0.8 | 1.5 | 54.3% | |
Book value per share (Unadj.) | Rs | 179.9 | 963.6 | 18.7% | |
Shares outstanding (eoy) | m | 80.69 | 23.03 | 350.4% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 4.8 | 26.7% | |
Avg P/E ratio | x | 11.9 | 34.7 | 34.2% | |
P/CF ratio (eoy) | x | 7.2 | 27.3 | 26.5% | |
Price / Book Value ratio | x | 1.4 | 6.0 | 23.5% | |
Dividend payout | % | 9.4 | 50.8 | 18.6% | |
Avg Mkt Cap | Rs m | 20,306 | 132,078 | 15.4% | |
No. of employees | `000 | 0.8 | 3.3 | 25.1% | |
Total wages/salary | Rs m | 5,355 | 4,068 | 131.6% | |
Avg. sales/employee | Rs Th | 19,252.7 | 8,393.8 | 229.4% | |
Avg. wages/employee | Rs Th | 6,459.5 | 1,232.4 | 524.2% | |
Avg. net profit/employee | Rs Th | 2,064.1 | 1,153.0 | 179.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 27,708 | 57.6% | |
Other income | Rs m | 265 | 897 | 29.6% | |
Total revenues | Rs m | 16,226 | 28,605 | 56.7% | |
Gross profit | Rs m | 4,103 | 6,235 | 65.8% | |
Depreciation | Rs m | 1,091 | 1,027 | 106.2% | |
Interest | Rs m | 944 | 7 | 13,491.4% | |
Profit before tax | Rs m | 2,334 | 6,098 | 38.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 624 | 2,292 | 27.2% | |
Profit after tax | Rs m | 1,711 | 3,806 | 45.0% | |
Gross profit margin | % | 25.7 | 22.5 | 114.2% | |
Effective tax rate | % | 26.7 | 37.6 | 71.1% | |
Net profit margin | % | 10.7 | 13.7 | 78.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 15,922 | 69.2% | |
Current liabilities | Rs m | 9,517 | 6,235 | 152.6% | |
Net working cap to sales | % | 9.4 | 35.0 | 26.9% | |
Current ratio | x | 1.2 | 2.6 | 45.3% | |
Inventory Days | Days | 110 | 64 | 173.6% | |
Debtors Days | Days | 35 | 21 | 167.0% | |
Net fixed assets | Rs m | 16,304 | 7,539 | 216.3% | |
Share capital | Rs m | 161 | 230 | 70.2% | |
"Free" reserves | Rs m | 12,907 | 21,962 | 58.8% | |
Net worth | Rs m | 14,516 | 22,192 | 65.4% | |
Long term debt | Rs m | 4,189 | 0 | - | |
Total assets | Rs m | 29,805 | 29,839 | 99.9% | |
Interest coverage | x | 3.5 | 872.1 | 0.4% | |
Debt to equity ratio | x | 0.3 | 0 | - | |
Sales to assets ratio | x | 0.5 | 0.9 | 57.7% | |
Return on assets | % | 8.9 | 12.8 | 69.7% | |
Return on equity | % | 11.8 | 17.2 | 68.7% | |
Return on capital | % | 17.5 | 27.5 | 63.7% | |
Exports to sales | % | 24.8 | 0 | - | |
Imports to sales | % | 3.7 | 0 | - | |
Exports (fob) | Rs m | 3,956 | NA | - | |
Imports (cif) | Rs m | 596 | NA | - | |
Fx inflow | Rs m | 4,952 | 7,587 | 65.3% | |
Fx outflow | Rs m | 697 | 7,145 | 9.8% | |
Net fx | Rs m | 4,255 | 442 | 962.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 3,739 | 74.5% | |
From Investments | Rs m | -1,529 | -731 | 209.2% | |
From Financial Activity | Rs m | -941 | -1,972 | 47.7% | |
Net Cashflow | Rs m | 316 | 1,036 | 30.5% |
Indian Promoters | % | 61.4 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 60.4 | - | |
Indian inst/Mut Fund | % | 3.7 | 14.4 | 25.7% | |
FIIs | % | 12.7 | 14.6 | 87.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.1 | 10.5 | 210.5% | |
Shareholders | 46,261 | 15,184 | 304.7% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: GSK PHARMA ASTRAZENECA PHARMA DIVIS LABORATORIES IPCA LABS NATCO PHARMA
Compare DISHMAN PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
A fresh spike in US bond yields and a firm dollar triggered a selloff in Asian share markets today.
For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
An Indian company founded three decades ago in a garage caught my attention...
More